|
Non-Small Cell Lung Carcinoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
The pseudogene DUXAP10 promotes an aggressive phenotype through binding with LSD1 and repressing LATS2 and RRAD in non small cell lung cancer.
|
28029651 |
2017 |
|
Malignant neoplasm of breast
|
0.330 |
Biomarker
|
disease |
BEFREE |
In transfection assays, PA-PEG1k-RGD showed significantly higher transfection efficiency in comparison with PAM-ABP or PA-PEG1k-RAD in αvβ3/5 positive MCF7 breast cancer and PANC-1 pancreatic cancer cells.
|
24894645 |
2014 |
|
Non-Small Cell Lung Carcinoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
Importantly, validation studies from multiple cell lines revealed that BRG1 reexpression led to substantial changes in the expression of CDH1, CDH3, EHF, and RRAD that commonly undergo silencing by other epigenetic mechanisms during NSCLC development.
|
24445599 |
2014 |
|
Breast Carcinoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
In transfection assays, PA-PEG1k-RGD showed significantly higher transfection efficiency in comparison with PAM-ABP or PA-PEG1k-RAD in αvβ3/5 positive MCF7 breast cancer and PANC-1 pancreatic cancer cells.
|
24894645 |
2014 |
|
Malignant neoplasm of breast
|
0.330 |
PosttranslationalModification
|
disease |
BEFREE |
We conclude that epigenetic silencing of RRAD is a frequent event in lung and breast cancers, and analysis of it may provide novel opportunities for prognosis and therapy of these cancers.
|
17195088 |
2007 |
|
Malignant neoplasm of breast
|
0.330 |
Biomarker
|
disease |
CTD_human |
We conclude that epigenetic silencing of RRAD is a frequent event in lung and breast cancers, and analysis of it may provide novel opportunities for prognosis and therapy of these cancers.
|
17195088 |
2007 |
|
Non-Small Cell Lung Carcinoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Loss of RRAD expression was found in 14 of 20 (70%) NSCLC cell lines, 11 of 11 (100%) SCLC cell lines, and 8 of 10 (80%) breast cancer cell lines; expression was not affected in normal bronchial and mammary epithelial cells.
|
17195088 |
2007 |
|
Non-Small Cell Lung Carcinoma
|
0.330 |
Biomarker
|
disease |
CTD_human |
Methylation and gene silencing of the Ras-related GTPase gene in lung and breast cancers.
|
17195088 |
2007 |
|
Breast Carcinoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Loss of RRAD expression was found in 14 of 20 (70%) NSCLC cell lines, 11 of 11 (100%) SCLC cell lines, and 8 of 10 (80%) breast cancer cell lines; expression was not affected in normal bronchial and mammary epithelial cells.
|
17195088 |
2007 |
|
Breast Carcinoma
|
0.330 |
Biomarker
|
disease |
CTD_human |
Loss of RRAD expression was found in 14 of 20 (70%) NSCLC cell lines, 11 of 11 (100%) SCLC cell lines, and 8 of 10 (80%) breast cancer cell lines; expression was not affected in normal bronchial and mammary epithelial cells.
|
17195088 |
2007 |
|
Malignant neoplasm of breast
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
None of the three RAD genes demonstrated somatic mutations in breast cancer cell lines.
|
10463575 |
1999 |
|
Breast Carcinoma
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
None of the three RAD genes demonstrated somatic mutations in breast cancer cell lines.
|
10463575 |
1999 |
|
Cardiomegaly
|
0.310 |
Biomarker
|
phenotype |
LHGDN |
Rad GTPase deficiency leads to cardiac hypertrophy.
|
18056528 |
2007 |
|
Cardiomegaly
|
0.310 |
Biomarker
|
phenotype |
CTD_human |
Rad GTPase deficiency leads to cardiac hypertrophy.
|
18056528 |
2007 |
|
Mammary Neoplasms, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
Methylation and gene silencing of the Ras-related GTPase gene in lung and breast cancers.
|
17195088 |
2007 |
|
Cardiac Hypertrophy
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Rad GTPase deficiency leads to cardiac hypertrophy.
|
18056528 |
2007 |
|
Mammary Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Methylation and gene silencing of the Ras-related GTPase gene in lung and breast cancers.
|
17195088 |
2007 |
|
Mammary Carcinoma, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
Methylation and gene silencing of the Ras-related GTPase gene in lung and breast cancers.
|
17195088 |
2007 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Low RRAD levels were significantly correlated with large tumor size and advanced tumor stage; high ACTG1 levels were significantly correlated with advanced tumor stage.
|
30881024 |
2019 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Finally, the mechanistic experiments indicate that DUXAP10 could interact with Histone demethylase Lysine specific demethylase1 (LSD1) and repress tumor suppressors Large tumor suppressor 2 (LATS2) and Ras-related associated with diabetes (RRAD) transcription in NSCLC cells.
|
28029651 |
2017 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Functionally, RRAD contributes to the activation of STAT3 and expression of the stem cell factors OCT4, NANOG, and SOX2, thereby enhancing self-renewing ability, tumor sphere formation, EMT, and in vivo tumorigenesis.
|
25313011 |
2014 |
|
Neoplasms
|
0.070 |
GeneticVariation
|
group |
BEFREE |
Finally, RRAD overexpression in T29H cells inhibited tumor formation in nude mice, suggesting that RRAD is a tumor suppressor gene.
|
24648519 |
2014 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Expression of IGF2 was higher in tumors than in healthy lung tissue in never-smokers (p=0.003), and expression of AHR (p<0.0001), CSF1R (p<0.0001) and RRAD (p<0.0001) was lower in tumors than in healthy lung tissue in smokers.
|
24451080 |
2013 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
These results indicate that RRAD might act as a functional tumor suppressor and its epigenetic inactivation may play an important role in NPC development.
|
22487779 |
2012 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
We employed southern analysis to examine homology between yeast genes RAD 51, RAD 52, RAD 54, and RAD 55 for possible gamma repair genes in radioresistant or repair proficient human tumor cell lines and normal placental DNA.
|
3045425 |
1988 |